<p>Ligand Pharmaceuticals（納斯達克股票代碼：LGND）在過去三個月內被 4 位分析師分析，顯示出從看漲到看跌的多樣化觀點。</p>
<p>下表提供了他們最近評級的快速概述，突出了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
<table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<p>分析師對 12 個月價格目標的評估提供了額外的見解，顯示出平均目標為 182.0 美元，最高預估為 206.00 美元，最低預估為 162.00 美元。當前平均價格目標超過之前的 154.25 美元，增加了 17.99%。</p>
<p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1756850481_0.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="價格目標圖表" original-src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1756850481_0.png"/></p>
<h2>理解分析師評級：全面解析</h2>
<p>通過審查近期分析師的行動，我們可以深入瞭解金融專家如何看待 Ligand Pharmaceuticals。以下總結概述了主要分析師、他們的近期評估以及對評級和價格目標的調整。</p>
<table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>上調</td>
<td>買入</td>
<td>175.00 美元</td>
<td>160.00 美元</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright \u0026 Co.</td>
<td>上調</td>
<td>買入</td>
<td>206.00 美元</td>
<td>157.00 美元</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超越市場</td>
<td>185.00 美元</td>
<td>155.00 美元</td>
</tr>
<tr>
<td>Trevor Allred</td>
<td>Oppenheimer</td>
<td>上調</td>
<td>超越市場</td>
<td>162.00 美元</td>
<td>145.00 美元</td>
</tr>
</tbody>
</table>
<h3>關鍵見解：</h3>
<ul>
<li><strong>採取的行動：</strong> 針對市場動態和公司表現的變化，分析師更新他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，都表明他們對 Ligand Pharmaceuticals 近期發展的反應。這為分析師對公司當前狀態的看法提供了見解。</li>
<li><strong>評級：</strong> 分析師提供全面分析，給出定性評估，範圍從 “超越市場” 到 “表現不佳”。這些評級反映了對 Ligand Pharmaceuticals 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 分析師評估價格目標的動態，提供對 Ligand Pharmaceuticals 股票未來價值的估計。這一比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
<p>將這些分析師評估與相關財務指標結合分析，可以提供對 Ligand Pharmaceuticals 市場地位的全面視角。保持信息靈通，並藉助我們的評級表做出數據驅動的決策。</p>
<p>隨時瞭解 Ligand Pharmaceuticals 的分析師評級。</p>
<h2>發現 Ligand Pharmaceuticals：更深入的瞭解</h2>
<p>Ligand Pharmaceuticals Inc 是一家生物製藥公司，專注於開發和獲取有助於藥物創造的技術。該公司與多家制藥和生物技術公司建立了合作關係和許可協議。Ligand 的商業模式基於藥物發現、早期藥物開發、產品改良和合作。公司的收入主要由三個部分組成：來自商業化產品的特許權使用費、許可和里程碑付款，以及其商標 Captisol 材料的銷售。</p>
<h3>關鍵指標：Ligand Pharmaceuticals 的財務健康狀況</h3>
<p><strong>市值分析：</strong> 公司的市值低於行業基準，面臨規模限制。這可能受到增長預期或運營能力等因素的影響。</p>
<p><strong>積極的收入趨勢：</strong> 對 Ligand Pharmaceuticals 的財務狀況進行 3 個月的審查顯示出積極的敍述。截止 2025 年 6 月 30 日，該公司實現了顯著的收入增長率，達到了 <strong>14.68%</strong>，顯示出頂線收益的顯著增加。與同行相比，收入增長落後於行業同行。該公司的增長率低於醫療保健行業同行的平均水平。</p>
<p><strong>淨利潤率：</strong> Ligand Pharmaceuticals 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率達到 <strong>10.18%</strong>，展現出強大的盈利能力和有效的成本管理。</p>
<p><strong>股本回報率（ROE）：</strong> 公司的 ROE 表現突出，超過行業平均水平。ROE 達到 <strong>0.6%</strong>，展示了對股本資本的有效利用。</p>
<p><strong>資產回報率（ROA）：</strong> Ligand Pharmaceuticals 的 ROA 表現突出，超過行業平均水平。ROA 達到 <strong>0.52%</strong>，展示了對資產的有效利用和強勁的財務表現。</p>
<p><strong>債務管理：</strong> 該公司保持了平衡的債務管理，債務與股本比率低於行業標準，達到 <strong>0.01</strong>。</p>
<h2>分析師評級的基礎知識</h2>
<p>分析師在銀行和金融系統中工作，通常專注於股票或特定行業的報告。分析師可能會參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈股票的 “分析師評級”。分析師通常每季度對每隻股票進行一次評級。</p>
<p>分析師可能通過納入增長預期、收益和收入等指標的預測來增強他們的評估，為投資者提供額外的指導。重要的是要承認，儘管分析師在股票和行業方面是專家，但他們也是人，在提供見解時會表達自己的觀點。</p>
<p><strong>目前分析師推薦哪些股票？</strong></p>
<p>Benzinga Edge 讓您即時獲取所有主要分析師的評級上調、下調和價格目標。可以按準確性、上漲潛力等進行排序。點擊這裏以領先市場。</p>
<p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>

Ligand制藥

<p>Ligand Pharmaceuticals（納斯達克代碼：LGND）在過去三個月內獲得了 4 位分析師的混合評級，12 個月的平均目標價為 182.00 美元，比之前的目標上漲了 17.99%。最近的升級包括 Benchmark 和 HC Wainwright 給予的 “買入” 評級，目標價分別提高至 175.00 美元和 206.00 美元。該公司展現出強勁的財務健康狀況，淨利潤率為 10.18%，股本回報率為 0.6%。分析師的評估反映了他們對市場動態和公司表現的回應，為 Ligand 的市場地位提供了洞察</p>

<p>Ligand Pharmaceuticals (NASDAQ: LGND) has been analyzed by 4 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.</p>
<div class="lb-trans"><p>Ligand Pharmaceuticals（納斯達克股票代碼：LGND）在過去三個月內被 4 位分析師分析，顯示出從看漲到看跌的多樣化觀點。</p>
</div><p>The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.</p>
<div class="lb-trans"><p>下表提供了他們最近評級的快速概述，突出了過去 30 天情緒的變化，並與前幾個月進行了比較。</p>
</div><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>Bullish</strong></th>
<th align="right"><strong>Somewhat Bullish</strong></th>
<th align="right"><strong>Indifferent</strong></th>
<th align="right"><strong>Somewhat Bearish</strong></th>
<th align="right"><strong>Bearish</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Total Ratings</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>Last 30D</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1M Ago</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2M Ago</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3M Ago</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th></th>
<th align="right"><strong>看漲</strong></th>
<th align="right"><strong>稍微看漲</strong></th>
<th align="right"><strong>無所謂</strong></th>
<th align="right"><strong>稍微看跌</strong></th>
<th align="right"><strong>看跌</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>總評級</strong></td>
<td align="right">2</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>過去 30 天</strong></td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>1 個月前</strong></td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>2 個月前</strong></td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td><strong>3 個月前</strong></td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
</div><p>Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $182.0, with a high estimate of $206.00 and a low estimate of $162.00. Surpassing the previous average price target of $154.25, the current average has increased by 17.99%.</p>
<div class="lb-trans"><p>分析師對 12 個月價格目標的評估提供了額外的見解，顯示出平均目標為 182.0 美元，最高預估為 206.00 美元，最低預估為 162.00 美元。當前平均價格目標超過之前的 154.25 美元，增加了 17.99%。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.benzinga.com/files/images/story/2025/1756850481_0.png" alt="price target chart" original-src="https://www.benzinga.com/files/images/story/2025/1756850481_0.png"/></p>
<h2>Understanding Analyst Ratings: A Comprehensive Breakdown</h2>
<div class="lb-trans"><h2>理解分析師評級：全面解析</h2>
</div><p>In examining recent analyst actions, we gain insights into how financial experts perceive Ligand Pharmaceuticals. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.</p>
<div class="lb-trans"><p>通過審查近期分析師的行動，我們可以深入瞭解金融專家如何看待 Ligand Pharmaceuticals。以下總結概述了主要分析師、他們的近期評估以及對評級和價格目標的調整。</p>
</div><table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>Raises</td>
<td>Buy</td>
<td>$175.00</td>
<td>$160.00</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright &amp; Co.</td>
<td>Raises</td>
<td>Buy</td>
<td>$206.00</td>
<td>$157.00</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>Raises</td>
<td>Outperform</td>
<td>$185.00</td>
<td>$155.00</td>
</tr>
<tr>
<td>Trevor Allred</td>
<td>Oppenheimer</td>
<td>Raises</td>
<td>Outperform</td>
<td>$162.00</td>
<td>$145.00</td>
</tr>
</tbody>
</table>
<div class="lb-trans"><table>
<thead>
<tr>
<th>分析師</th>
<th>分析師公司</th>
<th>採取的行動</th>
<th>評級</th>
<th>當前價格目標</th>
<th>之前價格目標</th>
</tr>
</thead>
<tbody>
<tr>
<td>Robert Wasserman</td>
<td>Benchmark</td>
<td>上調</td>
<td>買入</td>
<td>175.00 美元</td>
<td>160.00 美元</td>
</tr>
<tr>
<td>Joseph Pantginis</td>
<td>HC Wainwright \u0026 Co.</td>
<td>上調</td>
<td>買入</td>
<td>206.00 美元</td>
<td>157.00 美元</td>
</tr>
<tr>
<td>Douglas Miehm</td>
<td>RBC Capital</td>
<td>上調</td>
<td>超越市場</td>
<td>185.00 美元</td>
<td>155.00 美元</td>
</tr>
<tr>
<td>Trevor Allred</td>
<td>Oppenheimer</td>
<td>上調</td>
<td>超越市場</td>
<td>162.00 美元</td>
<td>145.00 美元</td>
</tr>
</tbody>
</table>
</div><h3>Key Insights:</h3>
<div class="lb-trans"><h3>關鍵見解：</h3>
</div><ul>
<li><strong>Action Taken:</strong> Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ligand Pharmaceuticals. This offers insight into analysts' perspectives on the current state of the company.</li>
<li><strong>Rating:</strong> Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ligand Pharmaceuticals compared to the broader market.</li>
<li><strong>Price Targets:</strong> Analysts gauge the dynamics of price targets, providing estimates for the future value of Ligand Pharmaceuticals's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
<div class="lb-trans"><ul>
<li><strong>採取的行動：</strong> 針對市場動態和公司表現的變化，分析師更新他們的建議。無論是 “維持”、“上調” 還是 “下調” 他們的立場，都表明他們對 Ligand Pharmaceuticals 近期發展的反應。這為分析師對公司當前狀態的看法提供了見解。</li>
<li><strong>評級：</strong> 分析師提供全面分析，給出定性評估，範圍從 “超越市場” 到 “表現不佳”。這些評級反映了對 Ligand Pharmaceuticals 相對於更廣泛市場的表現預期。</li>
<li><strong>價格目標：</strong> 分析師評估價格目標的動態，提供對 Ligand Pharmaceuticals 股票未來價值的估計。這一比較揭示了分析師預期隨時間變化的趨勢。</li>
</ul>
</div><p>Analyzing these analyst evaluations alongside relevant financial metrics can provide a comprehensive view of Ligand Pharmaceuticals's market position. Stay informed and make data-driven decisions with the assistance of our Ratings Table.</p>
<div class="lb-trans"><p>將這些分析師評估與相關財務指標結合分析，可以提供對 Ligand Pharmaceuticals 市場地位的全面視角。保持信息靈通，並藉助我們的評級表做出數據驅動的決策。</p>
</div><p>Stay up to date on Ligand Pharmaceuticals analyst ratings.</p>
<div class="lb-trans"><p>隨時瞭解 Ligand Pharmaceuticals 的分析師評級。</p>
</div><h2>Discovering Ligand Pharmaceuticals: A Closer Look</h2>
<div class="lb-trans"><h2>發現 Ligand Pharmaceuticals：更深入的瞭解</h2>
</div><p>Ligand Pharmaceuticals Inc is a biopharmaceutical company focused on developing and acquiring technologies that aid in creating medicine. The company has partnerships and license agreements with various pharmaceutical and biotechnology companies. Ligand's business model is based on drug discovery, early-stage drug development, product reformulation, and partnerships. The company's revenue consists of three primary elements: royalties from commercialized products, license and milestone payments, and sale of its trademarked Captisol material.</p>
<div class="lb-trans"><p>Ligand Pharmaceuticals Inc 是一家生物製藥公司，專注於開發和獲取有助於藥物創造的技術。該公司與多家制藥和生物技術公司建立了合作關係和許可協議。Ligand 的商業模式基於藥物發現、早期藥物開發、產品改良和合作。公司的收入主要由三個部分組成：來自商業化產品的特許權使用費、許可和里程碑付款，以及其商標 Captisol 材料的銷售。</p>
</div><h3>Key Indicators: Ligand Pharmaceuticals's Financial Health</h3>
<div class="lb-trans"><h3>關鍵指標：Ligand Pharmaceuticals 的財務健康狀況</h3>
</div><p><strong>Market Capitalization Analysis:</strong> Positioned below industry benchmarks, the company's market capitalization faces constraints in size. This could be influenced by factors such as growth expectations or operational capacity.</p>
<div class="lb-trans"><p><strong>市值分析：</strong> 公司的市值低於行業基準，面臨規模限制。這可能受到增長預期或運營能力等因素的影響。</p>
</div><p><strong>Positive Revenue Trend:</strong> Examining Ligand Pharmaceuticals's financials over 3M reveals a positive narrative. The company achieved a noteworthy revenue growth rate of <strong>14.68%</strong> as of 30 June, 2025, showcasing a substantial increase in top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.</p>
<div class="lb-trans"><p><strong>積極的收入趨勢：</strong> 對 Ligand Pharmaceuticals 的財務狀況進行 3 個月的審查顯示出積極的敍述。截止 2025 年 6 月 30 日，該公司實現了顯著的收入增長率，達到了 <strong>14.68%</strong>，顯示出頂線收益的顯著增加。與同行相比，收入增長落後於行業同行。該公司的增長率低於醫療保健行業同行的平均水平。</p>
</div><p><strong>Net Margin:</strong> Ligand Pharmaceuticals's financial strength is reflected in its exceptional net margin, which exceeds industry averages. With a remarkable net margin of <strong>10.18%,</strong> the company showcases strong profitability and effective cost management.</p>
<div class="lb-trans"><p><strong>淨利潤率：</strong> Ligand Pharmaceuticals 的財務實力體現在其卓越的淨利潤率上，超過行業平均水平。該公司的淨利潤率達到 <strong>10.18%</strong>，展現出強大的盈利能力和有效的成本管理。</p>
</div><p><strong>Return on Equity (ROE):</strong> The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of <strong>0.6%,</strong> the company showcases effective utilization of equity capital.</p>
<div class="lb-trans"><p><strong>股本回報率（ROE）：</strong> 公司的 ROE 表現突出，超過行業平均水平。ROE 達到 <strong>0.6%</strong>，展示了對股本資本的有效利用。</p>
</div><p><strong>Return on Assets (ROA):</strong> Ligand Pharmaceuticals's ROA stands out, surpassing industry averages. With an impressive ROA of <strong>0.52%</strong>, the company demonstrates effective utilization of assets and strong financial performance.</p>
<div class="lb-trans"><p><strong>資產回報率（ROA）：</strong> Ligand Pharmaceuticals 的 ROA 表現突出，超過行業平均水平。ROA 達到 <strong>0.52%</strong>，展示了對資產的有效利用和強勁的財務表現。</p>
</div><p><strong>Debt Management:</strong> The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at <strong>0.01</strong>.</p>
<div class="lb-trans"><p><strong>債務管理：</strong> 該公司保持了平衡的債務管理，債務與股本比率低於行業標準，達到 <strong>0.01</strong>。</p>
</div><h2>The Basics of Analyst Ratings</h2>
<div class="lb-trans"><h2>分析師評級的基礎知識</h2>
</div><p>Analysts work in banking and financial systems and typically specialize in reporting for stocks or defined sectors. Analysts may attend company conference calls and meetings, research company financial statements, and communicate with insiders to publish &#34;analyst ratings&#34; for stocks. Analysts typically rate each stock once per quarter.</p>
<div class="lb-trans"><p>分析師在銀行和金融系統中工作，通常專注於股票或特定行業的報告。分析師可能會參加公司電話會議和會議，研究公司財務報表，並與內部人士溝通，以發佈股票的 “分析師評級”。分析師通常每季度對每隻股票進行一次評級。</p>
</div><p>Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.</p>
<div class="lb-trans"><p>分析師可能通過納入增長預期、收益和收入等指標的預測來增強他們的評估，為投資者提供額外的指導。重要的是要承認，儘管分析師在股票和行業方面是專家，但他們也是人，在提供見解時會表達自己的觀點。</p>
</div><p><strong>Which Stocks Are Analysts Recommending Now?</strong></p>
<div class="lb-trans"><p><strong>目前分析師推薦哪些股票？</strong></p>
</div><p>Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. Click here to stay ahead of the market.</p>
<div class="lb-trans"><p>Benzinga Edge 讓您即時獲取所有主要分析師的評級上調、下調和價格目標。可以按準確性、上漲潛力等進行排序。點擊這裏以領先市場。</p>
</div><p>This article was generated by Benzinga's automated content engine and reviewed by an editor.</p>
<div class="lb-trans"><p>本文由 Benzinga 的自動內容引擎生成，並由編輯審核。</p>
</div>

分析師們對 Ligand 製藥股票的評價